Immunoinformatics-Driven Strategies for Advancing Epitope-Based Vaccine Design for West Nile Virus
Copyright © 2023 American Pharmacists Association. Published by Elsevier Inc. All rights reserved..
The West Nile virus (WNV) is the causative agent of West Nile disease (WND), which poses a potential risk of meningitis or encephalitis. The aim of the study was to design an epitope-based vaccine for WNV by utilizing computational analyses. The epitope-based vaccine design process encompassed WNV sequence collection, phylogenetic tree construction, and sequence alignment. Computational models identified B-cell and T-cell epitopes, followed by immunological property analysis. Epitopes were then modeled and docked with B-cell receptors, MHC I, and MHC II. Molecular dynamics simulations further explored dynamic interactions between epitopes and receptors. The findings indicated that the B-cell epitope QINHHWHKSGSSIG, along with three T-cell epitopes (FLVHREWFM for MHC I, NPFVSVATANAKVLI for MHC II, and NAYYVMTVGTKTFLV for MHC II), successfully passed the immunological evaluations. These four epitopes were further subjected to docking and molecular dynamics simulation studies. Although each demonstrated favorable affinities with their respective receptors, only NAYYVMTVGTKTFLV displayed a stable interaction with MHC II during MDS analysis, hence emerging as a potential candidate for a WNV epitope-based vaccine. This study demonstrates a comprehensive approach to epitope vaccine design, combining computational analyses, molecular modeling, and simulation techniques to identify potential vaccine candidates for WNV.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:113 |
|---|---|
| Enthalten in: |
Journal of pharmaceutical sciences - 113(2024), 4 vom: 26. März, Seite 906-917 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Windah, Axl Laurens Lukas [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Computational analysis |
|---|
| Anmerkungen: |
Date Completed 19.03.2024 Date Revised 19.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.xphs.2023.11.025 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM36533328X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM36533328X | ||
| 003 | DE-627 | ||
| 005 | 20240319232348.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.xphs.2023.11.025 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1336.xml |
| 035 | |a (DE-627)NLM36533328X | ||
| 035 | |a (NLM)38042341 | ||
| 035 | |a (PII)S0022-3549(23)00501-4 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Windah, Axl Laurens Lukas |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Immunoinformatics-Driven Strategies for Advancing Epitope-Based Vaccine Design for West Nile Virus |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 19.03.2024 | ||
| 500 | |a Date Revised 19.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 American Pharmacists Association. Published by Elsevier Inc. All rights reserved. | ||
| 520 | |a The West Nile virus (WNV) is the causative agent of West Nile disease (WND), which poses a potential risk of meningitis or encephalitis. The aim of the study was to design an epitope-based vaccine for WNV by utilizing computational analyses. The epitope-based vaccine design process encompassed WNV sequence collection, phylogenetic tree construction, and sequence alignment. Computational models identified B-cell and T-cell epitopes, followed by immunological property analysis. Epitopes were then modeled and docked with B-cell receptors, MHC I, and MHC II. Molecular dynamics simulations further explored dynamic interactions between epitopes and receptors. The findings indicated that the B-cell epitope QINHHWHKSGSSIG, along with three T-cell epitopes (FLVHREWFM for MHC I, NPFVSVATANAKVLI for MHC II, and NAYYVMTVGTKTFLV for MHC II), successfully passed the immunological evaluations. These four epitopes were further subjected to docking and molecular dynamics simulation studies. Although each demonstrated favorable affinities with their respective receptors, only NAYYVMTVGTKTFLV displayed a stable interaction with MHC II during MDS analysis, hence emerging as a potential candidate for a WNV epitope-based vaccine. This study demonstrates a comprehensive approach to epitope vaccine design, combining computational analyses, molecular modeling, and simulation techniques to identify potential vaccine candidates for WNV | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Computational analysis | |
| 650 | 4 | |a Epitope-based vaccine | |
| 650 | 4 | |a Molecular docking | |
| 650 | 4 | |a Molecular dynamics simulations | |
| 650 | 4 | |a West Nile virus | |
| 650 | 7 | |a Epitopes, T-Lymphocyte |2 NLM | |
| 650 | 7 | |a Epitopes, B-Lymphocyte |2 NLM | |
| 650 | 7 | |a Vaccines, Subunit |2 NLM | |
| 700 | 1 | |a Tallei, Trina Ekawati |e verfasserin |4 aut | |
| 700 | 1 | |a AlShehail, Bashayer M |e verfasserin |4 aut | |
| 700 | 1 | |a Suoth, Elly Juliana |e verfasserin |4 aut | |
| 700 | 1 | |a Fatimawali |e verfasserin |4 aut | |
| 700 | 1 | |a Alhashem, Yousef N |e verfasserin |4 aut | |
| 700 | 1 | |a Halwani, Muhammad A |e verfasserin |4 aut | |
| 700 | 1 | |a AlShakhal, Mouayd M |e verfasserin |4 aut | |
| 700 | 1 | |a Aljeldah, Mohammed |e verfasserin |4 aut | |
| 700 | 1 | |a Alissa, Mohammed |e verfasserin |4 aut | |
| 700 | 1 | |a Alsuwat, Meshari A |e verfasserin |4 aut | |
| 700 | 1 | |a Almanaa, Taghreed N |e verfasserin |4 aut | |
| 700 | 1 | |a Alshehri, Ahmad A |e verfasserin |4 aut | |
| 700 | 1 | |a Rabaan, Ali A |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of pharmaceutical sciences |d 1961 |g 113(2024), 4 vom: 26. März, Seite 906-917 |w (DE-627)NLM000006394 |x 1520-6017 |7 nnns |
| 773 | 1 | 8 | |g volume:113 |g year:2024 |g number:4 |g day:26 |g month:03 |g pages:906-917 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.xphs.2023.11.025 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 113 |j 2024 |e 4 |b 26 |c 03 |h 906-917 | ||